NCT03478488 - Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC | Biotech Hunter

Enrollment

480

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

September 10, 2024

Study Completion Date

December 31, 2026

Conditions

Biliary Tract Neoplasms

Interventions

DRUG

KN035 plus Gemcitabine & oxaliplatin

KN035 a programmed death ligand immune check inhibitor Per Investigator decision

DRUG

Gemcitabine & oxaliplatin

The standard of care for the patients with unresectable/metastatic biliary tract cancer

Trial Locations (1)

The Chinese people's liberation army (PLA) 81hospital, Nanjing

All Listed Sponsors

lead

3D Medicines (Sichuan) Co., Ltd.

INDUSTRY